<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072315</url>
  </required_header>
  <id_info>
    <org_study_id>PLN-74809-IPF-201</org_study_id>
    <nct_id>NCT04072315</nct_id>
  </id_info>
  <brief_title>Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/</brief_title>
  <acronym>IPF-201</acronym>
  <official_title>A Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pliant Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pliant Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-part study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target
      engagement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 9, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Group 1 - open label, single dose, 1 arm; Group 2 - open label, 7 day dosing, 1 arm; Group 3 - randomized, placebo controlled, 28-day dosing, 3 arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Group 1 - no masking; Group 2 - no masking; Group 3 - double-blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a change from baseline in αVβ6 receptor occupancy in the lung as measured by PET (positron emission tomography) scan.</measure>
    <time_frame>Following 1 or 7 days of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PLN-74809 as measured by the incidence of adverse events.</measure>
    <time_frame>Following 1, 7, or 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events by treatment and dose.</measure>
    <time_frame>Following 1, 7, or 28 days of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PLN-74809 (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 (mid dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 (open label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 (low dose/blinded)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 (double blind)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 (mid dose/blinded)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 (double blind)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLN-74809</intervention_name>
    <description>PLN-74809</description>
    <arm_group_label>PLN-74809 (high dose)</arm_group_label>
    <arm_group_label>PLN-74809 (low dose/blinded)</arm_group_label>
    <arm_group_label>PLN-74809 (mid dose)</arm_group_label>
    <arm_group_label>PLN-74809 (mid dose/blinded)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Knottin tracer</intervention_name>
    <description>Radiotracer</description>
    <arm_group_label>PLN-74809 (high dose)</arm_group_label>
    <arm_group_label>PLN-74809 (low dose/blinded)</arm_group_label>
    <arm_group_label>PLN-74809 (mid dose)</arm_group_label>
    <arm_group_label>PLN-74809 (mid dose/blinded)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF, within 5 years prior to Screening,

          -  FVC %predicted ≥50% and ≤90%

          -  DLco (hemoglobin-adjusted) ≥30%

          -  Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if
             on a stable dose for at least 3 months

        Exclusion Criteria:

          -  Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
             not approved for that indication by the FDA

          -  Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
             ratio &lt;0.7

          -  Need for continuous oxygen supplementation, defined as &gt;15 hours/day

          -  Clinical evidence of active infection, including but not limited to bronchitis,
             pneumonia, sinusitis that can affect FVC measurement or IPF progression

          -  Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
             of Screening

          -  Smoking of any kind within 3 months of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Pliant Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <phone>clintrials@pliantrx.com</phone>
    <email>clintrials@pliantrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Mooney, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Henry Guo, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

